Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Pharmacyclics Inc PCYC

Healthcare Biotechnology
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:PCYC)

Goldman Sachs Talks Pfizer's Acquisition Deal Of Medivation

Benzinga.com  August 22, 2016

Ibrutinib (IMBRUVICA®) Phase Ib/II Data Show Promise in Patients with Chronic Graft-Versus-Host-Disease

PR Newswire May 31, 2015

Phase III HELIOS Study Results Show Ibrutinib (IMBRUVICA®) Combination Therapy Significantly Increased Progression-Free Survival in Previously-Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients

PR Newswire May 30, 2015

Ibrutinib (IMBRUVICA®) in Combination with Anti-PD-L1 Antibody (MEDI4736) Study Commences for Patients with Two Relapsed/Refractory Blood Cancers

PR Newswire May 28, 2015

European Medicines Agency Issues Positive Opinion, Recommends Full Approval of IMBRUVICA® (ibrutinib) to Treat Waldenstrom's Macroglobulinemia

PR Newswire May 22, 2015

New ibrutinib (IMBRUVICA®) Data to be Showcased at American Society of Clinical Oncology (ASCO) Annual Meeting

PR Newswire May 13, 2015

Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates

PR Newswire May 1, 2015

New Longer-Term IMBRUVICA® (ibrutinib) Data Show High Response Rates in Patients with Waldenstrom's Macroglobulinemia

PR Newswire April 9, 2015

Solid Tumor Study Investigating Ibrutinib (IMBRUVICA®) in Combination with Anti-PD-L1 Antibody (MEDI4736) Commences in Patients with Relapsed/Refractory Non-Small Cell Lung, Breast and Pancreatic Cancers

PR Newswire April 1, 2015
View More News ››

Opinion & Analysis (NDAQ:PCYC)

New ETF From BlackRock And Edelman

Benzinga.com  March 26, 2015
View More Opinion ››

Bullboard Posts (NDAQ:PCYC)

RE:RE: There are no triple tops

Long live the CUZ. He never gave a bad buy call
chubster56 - October 24, 2013

Upgrade today

Goldman Sachs upgraded Pharmacyclics (NASDAQ: PCYC) from Neutral to Buy with a price target of $170.00 (from $111.00). Analyst Navdeep...
skyhi0 - October 11, 2013

100 nope 33% higher

and kamer just told his followers all about it
BCsilver - September 27, 2013

RE: There are no triple tops

PCYC still headed for 100
cousinwoolie - February 23, 2013

There are no triple tops

PCYC is headed for a hundred
cousinwoolie - January 26, 2013

Chartplays.com sees PCYC as a buy today

PCYC is the focus free chart of the day from Chartplays.com today. They believe PCYC is a possible buy and present under what...
battlinal74 - August 27, 2002
View more Bullboard ››

Anfield Energy Inc

Anfield Energy Inc

Anfield Energy Inc. is a Canada-based uranium and vanadium development and near-term production company. A key asset in the ...
View More »